Ari M. Melnick, MD

Overview

Therapeutic Targeting of Oncogenic Transcription Factors

Transcription factors can induce profound and sustained phenotypic effects in cells by binding and altering the expression of thousands of genes. It is therefore not surprising that many of these factors have been shown to play critical roles in tumorigenesis, especially in the hematological malignancies. From the mechanistic standpoint transcription factors function by binding to a specific DNA consensus sequence, or by forming a complex with other transcription factors, and recruiting chromatin modifying complexes to their various genetic target loci. Because transcription factors mediate their action largely through protein-protein interactions rather than enzymatic activities they have been traditionally been regarded as "undruggable targets". However, we propose that this concept is outdated and that a rigorous study of the biochemical mechanism of action of these proteins can provide sufficient information for the rational design of therapeutic inhibitors. We hypothesize that it is possible to design potent, specific and clinically viable transcription factor inhibitors. Such transcription therapy drugs would be predicted to therapeutically reprogram tumor cells so that they would either die or cease to display the malignant phenotype. We further hypothesize that the downstream pathways of these transcription factors can be harnessed for the development of more potent combinatorial treatments that by offering powerful anti-tumor efficacy could reduce the need for cytotoxic drugs in the clinical setting. Finally, we predict that transcription therapy drugs could offer superior activity against chemo-resistant and semi-quiescent tumor repopulating cells, allowing for complete eradication of disease.

Transcriptional Programming in Normal and Malignant B-cells

Highlights

1
Nature · 2020
CCChristopher Chin ASAshley Stephen Doane OEOlivier Elemento EAEftychia Apostolou+2 more →AMAri M. Melnick
PMID: 33299181PMCID: PMC7855728DOISenior author212 citations
2
Science (New York, N.Y.) · 2023
CCChristopher Chin DBDarko Barisic ACAmy Chadburn ZCZhengming Chen+4 more →AMAri M. Melnick
PMID: 36656933PMCID: PMC10515739DOISenior author40 citations
3
Cancer discovery · 2021
MLMeng Li CMCem Meydan CCChristopher ChinCDCeyda Durmaz+1 more →AMAri M. Melnick
PMID: 33500244PMCID: PMC8178167DOISenior author217 citations

Publications

410

Funding

127 View NIH portfolio on RePORTER ↗

Active

29 grants

MPI
SPORE: Adressing Health Disparities in Lymphoma
National Cancer Institute · 2025–2030 · via MD Anderson Cancer Center· 3 renewals
U54CA302435-01
MPI
Collaborative Subcontract with University of Texas M.D. Anderson Cancer Center and Dr. Melnick
MD Anderson Cancer Center · 2024–2029
No publications yet
MDACC 253204-02
Co-I
Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy
National Cancer Institute · 2023–2028
R01CA282889-04
Co-I
Characterizing stem cell-like B cell subpopulations and dissecting their role in tumorigenesis
National Cancer Institute · 2023–2028
R01CA283327-01
MPI
Dysregulated mechanoimmunology of epigenetics-driven lymphomas
National Cancer Institute · 2023–2028 · via Georgia Institute of Technology
U01CA280984-01
KP
Translating molecular profiles into treatment approaches to target disparities in lymphoma
Leukemia & Lymphoma Society · 2024–2027 · via Emory University
LLS 7038-25
MPI
Targeting Unmet Needs For B-cell Lymphomas
Leukemia & Lymphoma Society · 2022–2027
LLS 7027-23 Project 1
MPI
Define genetically/epigenetically modified targets in the immune niche of DLBCLs- Project 2
Leukemia & Lymphoma Society · 2022–2027 · via University Health Network
UHN 224060-04
KP
Role of chromatin remodeling complex BAF in immunity and lymphoma
National Cancer Institute · 2024–2027
R00CA246080-03
KP
Mechanisms of CTL Resistance in HIV Reservoirs
National Institute of Allergy and Infectious Diseases · 2022–2027
R01AI170245-01A1
Co-I
BAF complex deregulation in lymphoma
National Cancer Institute · 2022–2027 · via MD Anderson Cancer Center
R01CA266279-01A1
MPI
Research Collaboration Agreement- Treeline Biosciences, Inc.
Treeline Biosciences INC · 2024–2027BioPharma Alliance
BP 240939-01
KP
Preventing follicular lymphoma progression and transformation through precision therapy
National Cancer Institute · 2022–2027
R01CA270245-01
KP
The Impact of Spaceflight and Radiation on Clonal Hematopoiesis
National Aeronautics and Space Administration · 2023–2027
80NSSC23K0832
Co-I
The impact of changes in chromatin architecture on cancer phenotypes and tumor progression
National Cancer Institute · 2025–2027 · via New York University School of Medicine (Grossman)
No publications yet
P01CA229068-06A1
MPI
Therapeutic Targeting of SIRT3 for Aggressive and Refractory Lymphomas
National Cancer Institute · 2023–2027
R01CA270243-03
MPI
Epigenetic basis and therapeutic interdiction of FL progression
Lymphoma Research Foundation · 2023–2027
LRF 226504-01
KP
Elucidating the role of follicular dendritic cells in EZH2-mutated follicular lymphoma
Lymphoma Research Foundation · 2024–2026
LRF 234088-01
Co-I
How the immune system becomes malignant
Starr Cancer Consortium · 2024–2026 · via Broad Institute Inc
I17-0131
KP
Characterizing the role of BCL10 somatic mutations in B cell lymphomas
Lymphoma Research Foundation · 2024–2026
LRF 234006-01
KP
Uncovering immune evasion mechanisms and therapeutic targets in B-cell lymphomas via macrophage reprogramming
Leukemia & Lymphoma Society · 2025–2026
LLS 3444-26
Co-I
Role of BCL10 somatic mutations in lymphomagenesis and response to BCR-targeted therapies
National Cancer Institute · 2020–2026
R01CA249843-01
MPI
Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche
National Cancer Institute · 2024–2026
P01CA272295-02
KP
The role of SPEN and NOTCH2 mutations in pathogenesis of DLBCL.
Lymphoma Research Foundation · 2024–2026
LRF 234091-01
Sub-PI
Understanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in Lymphoma
National Cancer Institute · 2023–2026 · via Memorial Sloan Kettering Cancer Center
R01CA274249-03
MPI
Precision epigenetic therapy for SETD2+/- B cell lymphomas
Lymphoma Research Foundation · 2023–2026
LRF 226510-01
Co-I
The role of chromatin loop extrusion in lymphomagenesis and therapeutic targeting - Project 1
Leukemia & Lymphoma Society · 2024–2026 · via University of Florida
USF 240838-01
MPI
Discovery and therapeutic targeting of novel mechanisms driving Double Hit Lymphomas
Leukemia & Lymphoma Society · 2023–2025
LLS 6679-24
Co-I
Role of the stromal microenvironment in B-cell lymphoma progression and immune escape
National Cancer Institute · 2019–2025
R01CA242069-01A1

Completed grants (98)

Co-I
Inhibiting EZH2 to improve CAR T immunotherapy in B-cell lymphomas
Gilead Sciences, Inc. · 2023–2025
GSI 231647-01
PI
The Role of SPEN as Tumor Suppressor in BN2 DLBCL
Leukemia & Lymphoma Society · 2022–2025
LLS 8031-23
PI
SETD2 and H1 Project
Epizyme · 2021–2025BioPharma Alliance
EI 214942-01
MPI
Targeting immune escape in Cluster 5 DLBCL
AstraZeneca Pharmaceuticals LP · 2021–2025Contract
SRA 215352-01
PI
Targeting Epigenetic Circuits in B-Cell Lymphomas
National Cancer Institute · 2018–2025· 4 renewals
R35CA220499-07
PI
Precision translation of therapeutic regimens for follicular lymphoma
Institute for Follicular Lymphoma Innovation, Inc. · 2022–2025
IFLI 227301-02
Co-I
Role of novel onco-histone mutations in B-cell malignancies
National Cancer Institute · 2019–2025
R01CA234561-01A1
PI
BioPharma Alliance Agreement- Janssen Research & Development
Janssen Research & Development, LLC · 2021–2025BioPharma Alliance
BP 220122-03
Sub-PI
Lymphoid Experimental Therapeutics Platform to Study Cooperative Signaling in Human Lymphomas
National Cancer Institute · 2020–2025 · via Cornell University - Ithaca
R01CA238745-04
MPI
The impact of changes in chromatin architecture on cancer phenotypes and tumor progression
National Cancer Institute · 2019–2025 · via New York University Medical Center· 2 renewals
P01CA229086-05
KP
Lymph node-targeted multistage chemoimmunotherapy for lymphoma
National Cancer Institute · 2020–2025 · via Georgia Tech Research Corporation
R01CA247484-03
Sub-PI
Understanding the in vivo impact of immunotherapies in splenic lymphoma by intravital three-photon microscopy
National Cancer Institute · 2023–2025 · via Cornell University - Ithaca
R21CA277513-02
PI
Elucidating the role of follicular dendritic cells in EZH2-mutated follicular lymphoma progression and transformation
The Asco Cancer Foundation · 2023–2024
ASCO 226835-01
Co-I
Mechanisms of dynamic chromatin reorganization regulating B-cell differentiation and Lymphomagenesis
Starr Cancer Consortium · 2023–2024
I16-068
KP
Utilizing EZH2 Inhibition to Improve Immune Therapies in Follicular Lymphoma
Follicular Lymphoma Foundation · 2022–2024
FLF 224362-02
MPI
Exploring the roles of EZH2 mutation for the development of double hit lymphoma and acquisition of chemotherapy resistance
Leukemia & Lymphoma Society · 2023–2024
LLS 3426-24
KP
Preventing follicular lymphoma progression and transformation through precision therapy
Leukemia & Lymphoma Society · 2021–2024
LLS 6641-22
Sub-PI
Core: Targeting Enhancer Dysfunction in Hematological Malignancy- Core B
Leukemia & Lymphoma Society · 2019–2024 · via University of Florida
LLS SCOR 7021-20 CORE B
Sub-PI
Targeting Enhancer Dysfunction in Hematological Malignancy- Project 5
Leukemia & Lymphoma Society · 2019–2024 · via University of Florida
LLS SCOR 7021-20
Co-I
Elucidating Metabolic Pathways Regulating Germinal Center B Cells And Derived Lymphomas
American Society of Hematology Inc · 2021–2024
ASH 210204-03
KP
Role of Chromatin Remodeling Complex BAF in Immunity and Lymphoma
National Cancer Institute · 2020–2024· 2 renewals
K99CA246080-02S1
KP
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer
National Cancer Institute · 2017–2023
P50CA211024-05
KP
Disruption of epigenetic regulation of enhancers in the germinal center reaction drives clonal evolution in Follicular Lymphoma
National Cancer Institute · 2020–2023Fellowship
F31CA254302-01
KP
Cohesin complex regulatory proteins and chromosomal architecture in normal and malignant B-cells
American Society of Hematology Inc · 2022–2023
ASH 220412-01
PI
Characterizing The Biological And Mechanistic Nature Of The Elusive Lymphoma Stem Cell
Tri-Institutional Stem Cell Initiative (Weill Cornell) · 2021–2023
Tri-Sci #2021-033
KP
Molecular and Translational Oncology Research
National Cancer Institute · 2017–2023Training
T32CA203702-01A1
KP
Understanding the role of SPEN in DLBCL
Lymphoma Research Foundation · 2021–2023
LRF 210839-01
Sub-PI
Biomaterials-based Germinal Center Niches for Understanding the B Cell Maturation and B cell receptor signaling
National Institute of Allergy and Infectious Diseases · 2018–2023 · via Cornell University - Ithaca
R01AI132738-02
PI
Epizyme BPA Pre-Clinical Studies of EZH2 Inhibitor initiating Immunotherapy against B-Cell Lymphoma
Epizyme · 2021–2022BioPharma Alliance
BP 220027-01
Co-I
Mechanisms of dynamic chromatin reorganization regulating B-cell maturation and lymphomagenesis
Starr Cancer Consortium · 2021–2022
I14-0020
PI
SIRT3 TARGETED THERAPY FOR B-CELL LYMPHOMAS
Dr. Ralph and Marian Falk Medical Research Trust · 2019–2022
FALK 18448-20
Co-I
Standard Omics Measures for Astronauts (SOMA): Comprehensive Biomedical and Multiomic Profiling and the Aerospace Medicine Biobank
National Aeronautics and Space Administration · 2021–2022 · via Baylor College of Medicine
NNX16AO69A
Co-I
Beyond Apoptosis, Bcl-xL in Tumor Metastasis
National Cancer Institute · 2016–2022
R01CA204916-02
Sub-PI
Therapeutic Implications of Altered Epigenetics and DNA Damage Responses in Hematologic Disorders
Leukemia & Lymphoma Society · 2016–2022 · via University Health Network
UHN LLS 9238-16
MPI
MSK SPORE in Lymphoma
National Cancer Institute · 2016–2022 · via Sloan-Kettering Institute for Cancer Research· 2 renewals
P50CA192937-05
PI
MALT1 Degradation for the Treatment of Activated B-Cell Type Diffuse Large B-cell Lymphoma
Daedalus Fund for Innovation (Weill Cornell) · 2021–2022BioPharma Alliance
BP 220266-01
MPI
Targeting MALT1 to overcome resistance to immune checkpoint blockade in MCD-DLBCL
American Society of Hematology Inc · 2021–2022
ASH 212696-01
KP
Basic Junior Faculty ASH Scholar Award
American Society of Hematology Inc · 2020–2022
ASH 202414-01
KP
Signaling to Chromatin Pathways in Regulation of Germinal Center B Cell Differentiation and Lymphoma
Lymphoma Research Foundation · 2020–2022
LRF 200713-01
KP
TOX as a putative oncosuppressor in DLBCL
American Society of Hematology Inc · 2020–2022
ASH 202403-01
KP
The role of EZH2 in lymphomagenesis
U.S. Department of Defense · 2020–2022
No publications yet
W81XWH2010478
Sub-PI
Characterizing and Targeting the Follicular Lymphoma Microenvironment
Leukemia & Lymphoma Society · 2019–2022 · via INSERM Delegue Regional
LLS TRP6593-20
Sub-PI
Targeting deregulated epigenetic mechanisms in B-cell lymphomas.
Leukemia & Lymphoma Society · 2019–2022 · via University of Melbourne
UM 191547-03
MPI
Clonal co-evolution of cancer and immune cells - tumor genomics meets immunology
German Cancer Aid - Deutsche Krebshilfe · 2021–2022 · via University of Cologne
UC 70113307
MPI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)
National Cancer Institute · 2019–2022 · via Sloan-Kettering Institute for Cancer Research
UG1CA233332-03
Co-I
Biomaterials-based Germinal Center Niches for Understanding the B Cell Maturation and B cell receptor signaling
National Institute of Allergy and Infectious Diseases · 2020–2022 · via Georgia Institute of Technology
No publications yet
R01AI132728-04
PI
Understanding the role of SPEN in marginal zone B cell transformation using three-photon microscopy
Cornell University - Ithaca · 2021–2021
CUI 211701-01
PI
BPARC Agreement- Dr. Ari Melnick
Janssen Biotech Inc. · 2019–2021BioPharma Alliance
BP 200517-01
KP
Identifying therapeutic vulnerabilities of aggressive and therapy-resistant MCD/C5-DLBCLs.
American Society of Hematology Inc · 2020–2021
ASH 211129-01
PI
Targeting Unmet Clinical Needs for B-Cell Lymphoma
Leukemia & Lymphoma Society · 2016–2021
LLS 7012-16
PI
"Transcriptional regulation by hematopoietic BTB transcription factor"
Chemotherapy Foundation, Inc. · 2021–2021
CFI 212865-01
PI
Transcriptional Targeting in Cancer Therapy
Samuel Waxman Cancer Research Foundation · 2019–2021
No publications yet
SWCRF 200299-02
KP
Linker Histone Mutations Mediate Lymphomagenesis Through a Novel Chromatin Mechanism
U.S. Department of Defense · 2019–2021
W81XWH-19-1-0216
PI
Precision medicine deployment of mechanism based Epigenetic – Immune therapy for B-cell lymphoma
Leukemia & Lymphoma Society · 2018–2021
LLS-TRP-6572-19
KP
The role of BCL10 mutations in lymphomagenesis
Leukemia & Lymphoma Society · 2018–2021
5483-19
Sub-PI
Understanding and Targeting Chemotherapy Resistance in Acute Myeloid Leukemia
National Cancer Institute · 2015–2021 · via University of Pennsylvania
R01CA198089-05
PI
Design and testing of small molecule compound inhibitors of MALT1.
Janssen Biotech Inc. · 2018–2021Contract
BP 190099-02
PI
Defining the cellular origin and mechanistic basis for therapy resistant B-cell lymphomas
Starr Cancer Consortium · 2018–2020
I11-0027
PI
Sanofi Innovation Awards Program
Sanofi S.A. · 2019–2020BioPharma Alliance
BP 204239-01
KP
Nuclear Functions of BCL10 and MALT1 and Their Potential for Therapeutic Intervention in Non-Hodgkin's Lymphoma (DoD Career Development Award)
U.S. Department of Defense · 2015–2020
W81XWH-15-1-0418
KP
Defining the role of BTG1 mutation in driving a new form of therapy-resistant DLBCLs.
Leukemia & Lymphoma Society · 2018–2020
LLS 3384-19
PI
TRANSCRIPTIONAL REGULATION BY HEMATOPOIETIC BTB TRANSCRIPTION FACTORS
Chemotherapy Foundation, Inc. · 2018–2020
CFI 181146-02
KP
Mutations Disrupting Gene Enhancer Epigenetic Complexes as Drivers of Lymphomagenesis
Leukemia & Lymphoma Society · 2017–2020Career
5469-18
Co-I
Integrative Single-cell Analysis of Hematological Malignancies
Daiichi Sankyo Co., Ltd. · 2018–2020Contract
DS 192276-01
PI
Janssen-Cornell Subrecipient - Subaward Agreement Amendment No. 1 (Related to WRG# 192179)
Dana-Farber Cancer Institute · 2019–2020Contract
SRA 192205-01
MPI
LETSSGo: Lymphoma-on-Chip Engineered Technology for Single-Organoid Sequencing and Genomics
National Cancer Institute · 2017–2020 · via Cornell University - Ithaca
R33CA212968-03
MPI
MOU Service agreement for personnel cost for Katerina Hatzi
Memorial Sloan Kettering Cancer Center · 2019–2019Contract
SA 200691-01
KP
Elucidating the Etiologic Role of Linker Histone Mutations in Hematological Malignancy
Starr Cancer Consortium · 2016–2019
I9-A9-062
Sub-PI
Dr. Ralph and Marian Falk Medical Research Trust Awards Programs - Catalyst Award
Dr. Ralph and Marian Falk Medical Research Trust · 2018–2019 · via LLS
LLS 180230-01
KP
eRNA Processing by Integrator in Lymphoma Pathogenesis
National Cancer Center, Inc. · 2017–2019Fellowship
NCC 17060880-01
KP
Role of histone demethylated LSD1 as an epigenetic dependency in lymphoma
National Cancer Institute · 2016–2019
K99CA212276-02
KP
Use of Chromatin Accessibility Maps to Discover New Regulatory Circuits in Aggressive B Cell Lymphomas
National Cancer Institute · 2017–2019Fellowship
F31CA220981-02
PI
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
National Cancer Institute · 2014–2019· 3 renewals
R01CA187109-03S1
PI
Transcriptional Targeting in Cancer Therapy
Samuel Waxman Cancer Research Foundation · 2017–2019
No publications yet
SWCRF 180328-07
MPI
Cohesin Regulatory Proteins and Chromosomal Architecture in Normal and Malignant B-Cells
National Cancer Institute · 2018–2019
R01CA228528-01
PI
Janssen MALT1 Collaborative Project
Janssen Biotech Inc. · 2018–2019Contract
BP 192179-01
KP
Role of BTG1 Mutations in Lymphomagenesis
Lymphoma Research Foundation · 2017–2019Fellowship
LRF 17030307-01
MPI
ECOG-ACRIN Integrated Leukemia Translational Science Center
National Cancer Institute · 2014–2019 · via Montefiore Medical Center
U10CA180827-05
Sub-PI
Core C: Consortium For The Study of Chromatin Biology And Epigenetic Training In Hematological Malignancies
Leukemia & Lymphoma Society · 2015–2018 · via University of Florida
7006-13
Sub-PI
Project 6: Clinical Epigenetics in Hematological Malignancies
Leukemia & Lymphoma Society · 2015–2018 · via University of Florida
7006-13
Sub-PI
MALT1 Inhibitors for the Treatment of Chemo-Resistant ABC-DLBCL
National Cancer Institute · 2013–2018 · via Dana-Farber Cancer Institute
R01CA182736-05
PI
MALT1 Targeted Therapy for B-Cell Lymphoma
National Cancer Institute · 2014–2018
R01CA187492-04
KP
HERO - Differential Effects on Homozygous Twin Astronauts Associated with Differences in Exposure to Spaceflight Factors
National Aeronautics and Space Administration · 2014–2018
NNX14AH50G
KP
Role of TET Proteins in Mature B Cells and Lymphomagenesis
Lymphoma Research Foundation · 2016–2018
LRF 16030472-01
KP
Cohesin Complex Proteins in Lymphomagenesis
Lymphoma Research Foundation · 2015–2018Fellowship
LRF 180151-02EWOF
MPI
Role of TET 2 Mutations in the Pathogenesis and Treatment of AML
National Cancer Institute · 2013–2018 · via Sloan-Kettering Institute for Cancer Research
R01CA173636-05
PI
Transcriptional Regulation by Hematopoietic BTB Transcription Factors
Chemotherapy Foundation, Inc. · 2016–2017
CFI 16040656-02
KP
Epigenetic Control of B-Cell Differentiation and Lymphomagenesis by Polycomb Complexes
American Society of Hematology Inc · 2015–2017
ASH 15020146-3
KP
Delineating Clinical Response with Single-Cell Omics
AbbVie Inc. · 2016–2017Contract
Abbvie RAA
KP
Epigenome Interactions in Complex Neurogenetic Disorders
National Institute of Neurological Disorders and Stroke · 2011–2017
R01NS076465-04
PI
LincMHeM-Role of DNA Methylation in the Regulation of lincRNAs in Hematological Malignancies
University of Navarra · 2013–2016
UoN 14030277-01
PI
Targeting the Heat Shock Response for the Therapy of DLBCL
National Cancer Institute · 2011–2016
R01CA155226-05
Sub-PI
Chromatin Mechanisms and Epigenetic Targeting in Hematological Malignancies
Leukemia & Lymphoma Society · 2012–2015 · via Northwestern University
7006-13
PI
Transcriptional Silencing by the BCL6 Oncoprotein
National Cancer Institute · 2010–2015
R01CA104348-10
KP
Center on the Microenvironment and Metastasis
National Cancer Institute · 2009–2015 · via Cornell University - Ithaca
U54CA143876-05
PI
Molecular Targeting of Diffuse Large B-cell Lymphoma
National Cancer Institute · 2010–2014
R01CA143032-05
PI
The BTB pocket as a novel cancer therapy target
NCI · 2002–2004 · via NIH RePORTER
R21CA099982-02
PI
TRANSCRIPTIONAL REGULATION BY THE PLZF PROTEIN
NCI · 1997–2002 · via NIH RePORTER
K08CA073762-05

Honors & distinctions

Member · American Society for Clinical Investigation · 2009
Member · Association of American Physicians

Clinical research

Completed & closed trials (1)

PI
Role of chromatin remodeling complex BAF in immunity and lymphoma
Weill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)

Available technologies

3 View full WCM portfolio ↗

News mentions

22 View all WCM news ↗

A Unifying Mechanism for Cancer-Driving Mutations
October 28, 2026
A family of mutations seen in about 20% of human cancers drives malignancy by changing the accessibility of genes to a particular regulatory protein, according to a study by Weill Cornell Medicine investigators.
Awards & Honors: March 2025
March 31, 2025
Awards, honors and achievements for the month of March.
Anticancer Drugs Could Make Immunotherapies More Effective
December 5, 2024
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.
NIH Grant Will Support Lymphoma Research
August 15, 2024
Weill Cornell Medicine has received a five-year, $12.4 million grant from the National Cancer Institute, part of the National Institutes of Health, for an extensive program of basic and translational research on the biology of diffuse large B-cell lymphoma (DLBCL), the most common form of lymphoma.
Commercial Astronauts Shed Light on Flights’ Health Impacts and Create Spaceflight Atlas
June 11, 2024
Molecular and physiological changes in space travelers reveal new targets for aerospace medicine and can guide new missions, according to the results of a massive international research endeavor by investigators at Weill Cornell Medicine, SpaceX, and other organizations.

Show 17 more mentions

Faculty Members Honored with Distinguished Awards
May 16, 2024
Weill Cornell Medicine faculty members and alumni were honored with awards for their exemplary achievements in research, education and patient care during the institution’s commencement activities on May 15 and 16.
Discovery Suggests New Strategy Against Follicular Lymphoma
March 28, 2024
A team led by researchers at Weill Cornell Medicine has identified important drivers of the transformation of a type of blood cancer called follicular lymphoma from a slow-growing form to the aggressive form it takes in some patients.
Adding Epigenetic Drug to Standard Chemotherapy Was Effective in Pilot Study for T-cell Lymphoma
May 4, 2023
Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.
Weill Cornell Medicine Receives Grants to Advance Lymphoma Research
February 9, 2023
Two new grants from The Leukemia & Lymphoma Society (LLS) will support Weill Cornell Medicine’s pathbreaking research on the origins of lymphomas and on treatments that exploit these cancers’ biological vulnerabilities.
Lymphoma Mutation Yields Super-Competitive Immune Cells
January 20, 2023
The key to understanding how the most aggressive lymphomas arise and resist current therapies may lie in mutations that disrupt a critical natural selection process among antibody-producing B cells.
Study Reveals Cause, Potential Precision Therapies for Aggressive Type of Lymphoma
May 25, 2022
DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people with a mutation in a gene called SETD2, leading to a type of aggressive blood cancer.
Lymphoma Cell Metabolism May Provide New Cancer Target
January 3, 2022
Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study from researchers at Weill Cornell Medicine and Cornell’s Ithaca campus.
Antibody-Producing B Cells May be "Predestined" for their Fates
September 23, 2021
The master regulator behind the development of antibody-producing cells has been identified in a study by investigators at Weill Cornell Medicine. The findings provide new insight into the inner workings of the immune system and may help understand how tissues develop and how certain cancers arise.
Scientists Discover a Key Genetic Driver of Lymphomas
December 9, 2020
Mutations in proteins called histone H1, which help package DNA in chromosomes, are a frequent cause of lymphomas, according to a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and The Rockefeller University. The findings could lead to new approaches to treating these cancers.
Studies Reveal Clues about Preventing Spaceflight-Related Risks
November 25, 2020
Space travel, illnesses like COVID-19, and climbing Mount Everest can trigger the body’s stress response systems in similar ways, according to new studies by Weill Cornell Medicine, space agencies and many other investigators.
American Society of Hematology Recognizes Weill Cornell Physician-Scientist for Advancing Treatment of Blood Cancers with Epigenetic Research
September 2, 2020
Dr. Ari Melnick, the Gebroe Family Professor of Hematology/Oncology at Weill Cornell Medicine, has been awarded the American Society of Hematology's (ASH) 2020 Ernest Beutler Lecture and Prize for advancing treatment of acute myeloid leukemia through epigenetic research.
Scientists Build the First Global Database and Roadmap for CAR Therapy Clinical Trials
January 6, 2020
Weill Cornell Medicine scientists have built the first global database of clinical trials testing a rapidly expanding approach to cancer treatment that involves genetically modifying immune cells to recognize specific targets on a patient’s cancer cells and attack them.
Scientists Find Core Vulnerability In Aggressive Lymphomas
September 4, 2019
The most common type of non-Hodgkin lymphoma depends for its aggressive growth and survival on an enzyme that can be therapeutically targeted with a novel compound developed at Cornell University, scientists at Weill Cornell Medicine and Cornell’s Ithaca campus have discovered.
A One-Two Epigenetic Punch Against Aggressive Acute Myeloid Leukemia
August 28, 2019
Scientists at Weill Cornell Medicine have developed a system that uses cancer patients’ own cells to evaluate the efficacy of treatments. The scientists used their new testbed to show that a two-drug combination potentially would benefit many patients with acute myeloid leukemia (AML).
Blocking Ancient Stress Gene May Aid Cancer Treatment
May 9, 2019
A gene that originally evolved to help vertebrates’ early ancestors respond to stress is co-opted by cancers to help them resist treatment, according to a study by Weill Cornell Medicine investigators.
Astronaut Twins Study Yields New Insights, Algorithms and Portable DNA Sequencing Tools
April 11, 2019
Long-term spaceflight causes more changes to gene expression than shorter trips, especially to the immune system and DNA repair systems, according to research by Weill Cornell Medicine and NASA investigators as part of NASA’s Twins Study, which followed the only set of identical twin astronauts for more than two years.
Two Advances in Understanding Lymphomas May Lead to New Therapies
January 23, 2019
New studies from Weill Cornell Medicine researchers have revealed the importance of two gene-regulation proteins in the development of common immune cell cancers called lymphomas.

Mentoring

3 All publications with mentees →

External relationships

Advisory/Scientific Board Member

Janssen Global Services, LLC

Other Interest

Treeline Biosciences INC

Other

AstraZeneca Pharmaceuticals LP · Casma Therapeutics, Inc. · Daiichi Sankyo, Inc. · Exscientia PLC · Ipsen Bioscience · Treeline Biosciences INC